There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MoonLake Immunotherapeutics (MLTX – Research Report), ATAI Life Sciences (ATAI – Research Report) and TScan Therapeutics (TCRX – Research Report) with bullish sentiments.
MoonLake Immunotherapeutics (MLTX)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on MoonLake Immunotherapeutics, with a price target of $75.00. The company’s shares closed last Friday at $56.14, close to its 52-week high of $63.40.
According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on MoonLake Immunotherapeutics is a Strong Buy with an average price target of $61.38, implying a 12.8% upside from current levels. In a report issued on August 10, LifeSci Capital also maintained a Buy rating on the stock with a $60.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
ATAI Life Sciences (ATAI)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on ATAI Life Sciences today and set a price target of $20.00. The company’s shares closed last Friday at $1.68, close to its 52-week low of $1.14.
According to TipRanks.com, Trucchio ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ATAI Life Sciences with a $15.33 average price target, implying a 791.3% upside from current levels. In a report issued on August 11, Berenberg Bank also reiterated a Buy rating on the stock with a $11.00 price target.
TScan Therapeutics (TCRX)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on TScan Therapeutics, with a price target of $15.00. The company’s shares closed last Friday at $2.06, close to its 52-week low of $1.45.
According to TipRanks.com, Fein is a 1-star analyst with an average return of
Currently, the analyst consensus on TScan Therapeutics is a Strong Buy with an average price target of $9.67, implying a 360.5% upside from current levels. In a report issued on August 10, Barclays also maintained a Buy rating on the stock with a $6.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MLTX:
- MoonLake Immunotherapeutics reports Q2 EPS (23c), consensus (27c)
- MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
- Three new option listings on August 9th
- MoonLake Immunotherapeutics price target raised to $86 from $61 at Wedbush
- MoonLake completes randomization of patients for Phase 2 trial
